OnKure is engaged in the discovery and development of epigenetic therapies for the treatment of cancer that include selective inhibitors of histone deacetylases (HDACs).
Our lead drug is OKI-179, a best-in-class Class 1 HDAC inhibitor. It has the potency of its IV-delivered rival Istodax (Romidepsin) but is delivered orally. In pre-clinical models of both hematological and solid tumor cancers, OKI-179 significantly and safely reduced the growth rate of tumors when dosed by itself or in combination with other targeted therapies. OKI-179 is nearing the end of a successful Phase 1 clinical trial and planning for Phase 2 is ongoing.
In addition, we are advancing our HDAC3 selective inhibitor, OKI-422, into pre-clinical toxicology studies. It has been demonstrated in pre-clinical models of non-Hodgkin’s lymphoma that selective HDAC3 inhibition can restore immune surveillance without triggering undesirable hematopoiesis effects. Finally, we have a program that has identified selective HDAC6 inhibitors that are among the most potent and selective agents reported to date.
OnKure operates as a virtual organization, relying on a group of veteran consultants and advisors to coordinate many of our pre-clinical and clinical development activities. This lean operating model allows us to retain considerable flexibility in the development of our products while minimizing capital expenditures and unnecessary overhead.